Compare · BVS vs SYK
BVS vs SYK
Side-by-side comparison of Bioventus Inc. (BVS) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BVS and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $118.40B, about 156.6x BVS ($756.0M).
- Over the past year, BVS is up 31.3% and SYK is down 19.2% - BVS leads by 50.5 points.
- BVS has been more active in the news (16 items in the past 4 weeks vs 8 for SYK).
- SYK has more recent analyst coverage (25 ratings vs 14 for BVS).
- Company
- Bioventus Inc.
- Stryker Corporation
- Price
- $8.84-2.43%
- $307.81-0.30%
- Market cap
- $756.0M
- $118.40B
- 1M return
- -13.04%
- +4.48%
- 1Y return
- +31.28%
- -19.25%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 16
- 8
- Recent ratings
- 14
- 25
Bioventus Inc.
Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company provides osteoarthritic joint pain treatment and joint preservation products, including Durolane, a single injection therapy; GELSYN-3, a three injection therapy; and SUPARTZ FX, a five injection therapy. It also offers bone graft substitutes comprising allograft-derived bone graft with growth factors, demineralized bone matrix, cancellous bone in different preparations, bioactive synthetics, collagen ceramic matrix, and bone marrow isolation systems. In addition, the company provides Exogen systems for the non-invasive treatment of established nonunion fractures and certain fresh fractures. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest BVS
- Director Bartholdson John A. converted options into 32,282 shares, increasing direct ownership by 41% to 111,902 units (SEC Form 4)
- Director Sutter Martin P converted options into 32,282 shares, increasing direct ownership by 38% to 117,523 units (SEC Form 4)
- Director Stalnecker Susan M converted options into 32,282 shares, increasing direct ownership by 30% to 138,239 units (SEC Form 4)
- Director Nohra Guy P converted options into 32,282 shares, increasing direct ownership by 28% to 148,892 units (SEC Form 4)
- Director Neels Guido J converted options into 32,282 shares, increasing direct ownership by 38% to 117,523 units (SEC Form 4)
- Director Hawkins William A converted options into 39,789 shares, increasing direct ownership by 15% to 297,640 units (SEC Form 4)
- Director Ladone Mary Kay converted options into 32,282 shares, increasing direct ownership by 41% to 111,263 units (SEC Form 4)
- Director Mcmurry-Heath Michelle converted options into 32,282 shares, increasing direct ownership by 72% to 77,279 units (SEC Form 4)
- Director Cowdy Philip G. converted options into 32,282 shares, increasing direct ownership by 276% to 43,982 units (SEC Form 4)
- Director Beyer Pat converted options into 32,282 shares, increasing direct ownership by 42% to 108,718 units (SEC Form 4)
Latest SYK
- President and COO Stiles Spencer S gifted 1,607 shares, decreasing direct ownership by 2% to 76,027 units (SEC Form 4)
- Stryker launches TPX HD® power tool, supporting demanding orthopaedic procedures
- VP, Chief Legal Officer Fletcher Robert S sold $1,394,409 worth of shares (4,544 units at $306.87) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 10,582 units (SEC Form 4)
- Director Stryker Ronda E sold $96,792,669 worth of shares (310,000 units at $312.23) (SEC Form 4)
- Stryker Launches Pangea Plating System and Completes First Case in Europe
- SEC Form SD filed by Stryker Corporation
- SEC Form 8-K filed by Stryker Corporation
- BioStar Capital-Backed Amplitude Vascular Systems' $835M Acquisition by Stryker Reflects Strength of Michigan's Medtech Ecosystem
- VP, Chief HR Officer Fink M Kathryn exercised 21,582 shares at a strike of $167.98, covered exercise/tax liability with 16,362 shares and sold $2,473,756 worth of shares (8,720 units at $283.69) (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation